This research study is for patients with a type of cancer called recurrent endometrial carcinoma, which has a problem in its DNA repair system, known as deficient mismatch repair system (dMMR). The study wants to see if two medicines, nivolumab and ipilimumab, can help better than nivolumab alone. These medicines are monoclonal antibodies, which help the immune system fight cancer.

In this study, some patients will get both medicines, while others will get just one. The study will check if tumors shrink or stop growing. It will also see how well patients live while on these treatments. To join, patients need a certain type of endometrial cancer and should have recovered from recent treatments.

• Study Duration: Patients are followed for up to 5 years.
• Treatment Visits: Every 3-4 weeks initially, then less often.
• Risks: Possible side effects from medications; frequent health checks needed.

Participants must be over 18, not pregnant, and should use contraception if of childbearing age. It's important to discuss with a doctor before joining to understand all details and eligibility requirements.